69results about How to "Process scaling is easy" patented technology

The invention discloses a hybridized perovskite microcrystal light-emitting material. The hybridized perovskite microcrystal light-emitting material comprises perovskite as shown in formula I AM2X5 and perovskite as shown in formula II A4MX6, wherein A is selected from at least one of CH3NH3<+>, NH=CHNH3<+>, C(NH2)3<+>, R2NH3<+>, Li<+>, Na<+>, Rb<+> or Cs<+>; R2 is selected from hydrogen, C1-C10 alkyl and C1-C10 unsaturated hydrocarbyl; M is metal ions, and the metal is selected from at least one of Ge, Sn, Pb, Sb, Bi, Cu, Mn, Sr, In, Tl and Ag; X is selected from at least one of halogen anions. The hybridized perovskite microcrystal light-emitting material is good in light-emitting efficiency and good in stability.

The invention discloses a method for preparing high-purity ApoA-I (Apolipoprotein A-I) from a plasma fraction IV through purification, comprising the following steps of: dissolving the participates of the plasma fraction IV, centrifuging to remove diatomite and impurities, and collecting a supernate; adding sodium chloride to the supernate so that ApoA-I protein is coagulated and separated out, and centrifuging to obtain an ApoA-I precipitate; redissolving the precipitate and filtrating; and enabling the filtrate to be sequentially subjected to anion column chromatography and hydrophobic column chromatography and separating to obtain a high-purity ApoA-I solution. The ApoA-I prepared by adopting the process disclosed by the invention has high purity capable of reaching more than 95 percent and the ApoA-I yield capable of reaching 70 percent and is safe and convenient to operate, easy to realize process amplification and very suitable for industrial production.

The invention relates to a mixed matrix membrane with heat resistance and solvent resistance and a preparation method and an application thereof and belongs to the field of membrane separation technologies and novel materials. The preparation method of the mixed matrix membrane with heat resistance and solvent resistance comprises the steps of preparing an original membrane of the mixed matrix membrane and performing thermal oxidative crosslinking, wherein the step of preparing an original membrane of the mixed matrix membrane comprises the following steps: preparing a membrane preparation liquid from graphene oxide, metal alkoxide, acetic acid, a polymer and an organic solvent and preparing the membrane; and performing in-situ synthesis of the mixed matrix membrane by means of a non-solvent phase inversion method. The original membrane has a lot of spongy holes and vertical dactylopore structures and meanwhile has a relatively high permeating separating property. The original membrane is subjected to thermal oxidative crosslinking to prepare the mixed matrix membrane with solvent resistance and thermal stability. The mixed matrix membrane not only can keep the porous structure and the high permeating separating property, but also has excellent solvent resistance and heat resistance.

The invention relates to uniform-sized konjak gulcomannan microspheres. The average particle size of the microspheres is less than 10 mu m; the content of the konjak gulcomannan in the microspheres is greater than 20% (w/w); the particle size is uniform; and the particle size distribution coefficient Span value is less than 0.9. The invention further provides a preparation method of the microspheres. According to the invention, the problems that the konjak gulcomannan microspheres of which the particle size is less than 10 mu m are hard to prepare by using the conventional method and the prepared microspheres are not uniform in particle size are solved.

The invention discloses a production technology of high-pure apolipoprotein Apoa-I from fourth deposit of a blood plasma component. The production technology is to prepare high-pure Apoa-I from fourth deposit of the blood plasma component through one step of centrifugation and one step of ion column chromatography. The production technology provided by the invention has advantages of simple equipment, convenient operation, few steps, short production period and high protein recovery rate, and is suitable for industrial large-scale production.

The invention discloses a preparation method for a biodegradable tissue engineering skin stent. The method comprises the following steps: adding carboxylation chitosan and sodium hyaluronate as auxiliary raw materials and adding NaCl as a pore-foaming agent into an aqueous solution of human collagen, stirring till fully dissolving all the added materials, adding glutamine transaminase as a bio-enzyme cross-linking agent for enzymatic cross-linking, and then refrigerating, performing vacuum freeze drying, removing salt and sterilizing by irradiating with Co60, thereby acquiring a degradable three-dimensional tissue engineering skin stent for repairing skin. The skin stent has high biocompatibility and excellent pore structure, is suitable for cell growth and can be used for treating full-thickness defect and scald.

The invention discloses a novel human-like collagen haemostatic dressing which has good biocompatibility, can be absorbed and is rich in calcium, zinc, copper and iron, and discloses a preparation method of the novel human-like collagen haemostatic dressing. The preparation method comprises the following steps: by taking modified protein obtained by chelating humanized human-like collagen prepared by high-density fermentation with calcium, zinc, copper and iron ions respectively as a raw material as well as taking lysyloxidase existing in mammals as a cross-linking agent, carrying out low-temperature cross-linking reaction and freeze-drying processes to obtain the novel collagen haemostatic dressing which can be used for hemostasis of wounds and postoperative hemostasis. The preparation method disclosed by the invention has the advantages that the raw materials are easy to obtain, the cost is low, the synthetic process is simple and easy to realize, process amplification is easy, and the reproducibility is good; and the human-like collagen haemostatic dressing prepared by the preparation method does not have animal-derived virus hidden danger, has an obvious haemostatic effect, can be used for hemostasis of various wounds and postoperative hemostasis, and can be used for basic research and application of related fields, such as biomedical tissue engineering.

The present invention provides a preparation method of fluor-hydroxyapatite nanoshuttle. The preparation method comprises the following steps: adding an aqueous calcium salt solution, an aqueous phosphate solution and a fluoride solution into a mixture of oleic acid, oleylamine and ethanol, and performing mineralization at 0-30 DEG C to obtain the pure fluor-hydroxyapatite nanoshuttle. The nanoshuttle prepared by the preparation method of fluor-hydroxyapatite nanoshuttle is uniform in shape and size, and can be used for preparing a biomedical repair material with controlled degradation property.

The invention discloses a washing method for an insulin crystal or an insulin analogue crystal. The method adopts a hollow fiber membrane to process insulin crystal suspension or insulin analogue crystal suspension. The effective combination of crystal washing, liquid changing and crystal suspension condensation, washing effects can be strengthened, and produce solvent residues and residue on ignition are low; The method can realize continuously automatic operation; and the method is simple in process and easy in operation, technology stability and production efficiency can be enhanced, and therefore, the method is especially suitable for applications on large-scale industrial production.

The invention discloses a rubidium-based high-selectivity separation membrane and a separation and enrichment method thereof. The rubidium-based high-selectivity separation membrane is prepared through a solvent evaporation method after a carrier, a base polymer, a synergist extractant, an organic solvent and the like are mixed and dissolved into a homogeneous solution. According to rubidium separation and enrichment, a high-selectivity rubidium membrane extraction device is used for efficiently extracting, separating and enriching rubidium from mixed feed liquid containing alkali metal ions such as rubidium, lithium and sodium under the acceleration of an external electric field. The separation membrane with high selectivity to rubidium ions provided by the invention is simple and convenient to prepare and stable in performance; rubidium extraction and reverse extraction are synchronous, the rubidium/sodium separation factor is high, the mass transfer process is stable, and continuousoperation can be achieved. Energy consumption is low, and secondary pollution is avoided. The rubidium-based high-selectivity separation membrane and the method can be used for separating and enriching low-concentration rubidium in high-sodium and high-lithium background solutions such as brine lithium extraction raffinate or lepidolite lithium extraction raffinate.

The invention relates to a preparation method of a water-phase cerium fluoride microparticle and application thereof, and belongs to the technical field of photocatalysis. The preparation method has the advantages that by using ceric ammonium nitrate or cerous nitrate as a cerium source, and using ammonium hexafluorotitanate or ammonium fluoride as a fluorine source, the water-phase cerium fluoride microparticle with good dispersivity is prepared by a simpler and mild preparation technology; the good phtocatalysis property is realized under the visible light condition, and the application field of cerium fluoride is widened.

The invention discloses a preparation method of sturgeon skin gelatin. The method comprises the following steps: air-drying fresh fish skins; soaking the dried fish skins with distilled water, performing ultrasonic treatment, cutting the fish skins into pieces, and performing alkaline water treatment and acid water treatment; and then extracting the well-treated fish skins by adopting an aqueous two-phase extraction method, and then performing centrifugation, concentration and drying to obtain the sturgeon skin gelatin. According to the preparation method of the sturgeon skin gelatin, the preparation time is short, the operation is simple, and the prepared sturgeon skin gelatin is high in protein content and purity, strong in gel strength, and light in fishy smell and has few impurities.

The invention discloses a preparation method of 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: with 1,3-dimethylpyrazole as a raw material, carrying out halogenation to obtain 4-halogenated-1,3,5-tetrahydronaphthalene; carrying out a reaction under the conditions of a bromination reagent and AIBN and hydrolysis with hexamethylenetetramine to obtain 4-halogen-1-methyl-1H-pyrazole-3-formaldehyde, then performing a reaction with a fluorination reagent to obtain 4-halogen-3-difluoromethyl-1-methylpyrazole; finally carrying out a reaction on the 4-halogen-3-difluoromethyl-1-methylpyrazole and a Grignard reagent to obtain 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester. The method is simple and convenient to operate and high in reaction yield, the purity of the obtained product can reach 99.5% or above, and the method has a potential process amplification prospect.

The invention relates to the field of pharmaceutical preparations, in particular to esomeprazole magnesium enteric-coated tablets and a preparation method thereof. Each esomeprazole magnesium enteric-coated tablet comprises (1) a table core comprising esomeprazole magnesium and pharmaceutical excipients, (2) an isolation layer comprising a coating material and an anti-adherent and (3) an enteric coating layer comprising a methacrylic acid copolymer and pharmaceutical excipients. The esomeprazole magnesium enteric-coated tablets adopt a simple preparation process and have the advantages of low requirement for equipment, high throughput, controllable product quality, good reproducibility, good stability and applicability to industrial production.

The invention discloses preparation and application of a novel hemagglutinin antigen used for preventing infection with the avian influenza virus. The preparation of the novel hemagglutinin antigen is characterized by comprising the following steps: (1) preparation of stable recombinant baculovirus (rBV) containing gene H10; (2) preparation of SVP of H10 expressed in Sf9 cells; and (3) purification and stabilization of SVP. The H10 recombinant hemagglutinin can be used for preventing infection with the avian influenza virus H10N8 and immunizing human beings or animals so as to produce antibodies and exert protective effects, and reacts with the antibodies against hemagglutinin H10N8 or H10; the H10 recombinant hemagglutinin has the characteristics of high efficiency and low cost and can be used for preventing the infection with the avian influenza virus H10N8; moreover, the recombinant hemagglutinin can be expressed in insect cells and does not depend on chicken embryos, so process scale-up and mass production of the recombinant hemagglutinin can be easily realized.

The invention discloses a preparation method of a novel vaterite-containing hydrogel scaffold material. The preparation method comprises the following steps: firstly, synthesizing vaterite from casein, Na2CO3 and CaCl2, then mixing the synthesized vaterite with a gelatin solution according to a certain ratio, respectively carrying out ion crosslinking and chemical crosslinking by virtue of an ammonium sulfate solution and a mixed solution of NHS (N-hydroxysuccinimide) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) in sequence; and carrying out freeze drying to obtain thenovel vaterite-rich hydrogel scaffold material. The hydrogel scaffold has good biocompatibility and mechanical properties, has large porosity and pore diameter, and can provide a very potential degradable biomedical material for enriching and optimizing a tissue defect degradable scaffold.

The invention belongs to the field of electronic packaging materials, and relates to a preparation method of a laminated graphene/metal composite for high-speed train IGBT packaging. The preparation method comprises the following steps that a metal foil is folded into a plurality of layers in an accordion manner, and an oxidized graphene solution with a finite concentration is prepared; the foldedmetal foil together with the oxidized graphene solution is transferred into a hydrothermal reaction kettle for hydrothermal reaction; after the reaction is completed, the metal foil plated with a graphene thin layer is transferred into a tube furnace for further thermal reduction; and an obtained graphene/metal foil is subjected to cold-pressed moulding and then hot-pressed sintering, so that thelaminated graphene/metal composite is obtained finally. The preparation method is simple in technological operation and low in cost, and facilitates process amplification; the composite is provided with a laminated structure so that the excellent plane heat conductivity of graphene can be exerted to the full extent. The plane heat conductivity of the prepared laminated graphene/metal composite is480-680 W/mK so that the heat dissipation requirement of the high-speed train IGBT packaging can be met.

The invention provides a polypeptide drug conjugate as well as a preparation method and application thereof. The polypeptide drug conjugate is prepared from ticagrelor and CREKA polypeptide, wherein the ticagrelor is connected with the CREKA polypeptide. Compared with the existing platelet inhibitor, the polypeptide drug conjugate provided by the invention not only can achieve high concentration enrichment of tumor tissue sites, but also realizes high concentration enrichment in atherosclerosis tissues by connecting the ticagrelor with the polypeptide, so that the platelet function in specificareas is inhibited without affecting platelet function during normal blood circulation, the bleeding risk of the conventional platelet inhibitor is reduced while the drug availability is improved, and better and safer tumor metastasis inhibition or acute coronary syndrome prevention function is accordingly realized.